Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Special Meeting of Stockholders of Matinas BioPharma Holdings, Inc. (the "Company") held on January 26, 2021 (the "Special Meeting"), our stockholders voted on the two proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on December 17, 2020 (the "Proxy Statement"). The final results for the votes regarding each proposal are set forth below.

1. At the Special Meeting our stockholders approved an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-15, with such reverse stock split to be effected at such ratio, time and date, if at all, as determined by our Board of Directors in its sole discretion (the "Reverse Stock Split Proposal"). The tabulation of votes with respect to this proposal was as follows:





    For        Against     Abstain
110,449,436   21,029,553   351,060

2. At the Special Meeting our stockholders approved the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the Reverse Stock Split Proposal. The tabulation of votes with respect to this proposal was as follows:





    For        Against     Abstain
110,084,391   21,248,603   497,055

Our Board has the discretion to determine, as it deems to be in the best interest of our stockholders, the specific ratio to be used within the range described above as well as the timing of a reverse stock split, if any. The Board may choose to exercise its discretion at any time prior to January 26, 2022, which is the first anniversary of its approval by our stockholders.

-2-

© Edgar Online, source Glimpses